Irinotecan is a medication used to manage and treat a variety of solid tumors. It is in the DNA topoisomerase I inhibitor class of drugs. Also known as CPT-11, irinotecan is used adjunctively with other therapeutic agents against colorectal cancer as a first- or second-line treatment. This activity reviews the indications, action, and contraindications for irinotecan as a valuable agent in treating solid tumors such as colorectal, pancreatic, ovarian, and lung cancers. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for healthcare team members in the care of patients who receive treatment with this medication.

**Objectives:**
- Identify the mechanism of action of irinotecan.
- Describe the adverse effects associated with irinotecan.
- Review the appropriate monitoring for Irinotecan.
- Explain the importance of collaboration and communication amongst the interprofessional team to ensure the optimal therapeutic results with irinotecan resulting in optimal patient outcomes.